Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
What does it do?
Perrigo makes the store-brand versions of medicines you already know — think the CVS or Walmart label on a box of cold medicine, allergy pills, or baby formula. When you grab the cheaper version of NyQuil or Claritin off the shelf, there's a good chance Perrigo made it. They sell these products across the US and Europe, covering everything from antacids to infant formula. Essentially, they are the behind-the-scenes factory that lets retailers offer cheaper alternatives to big-name drugs.
Store-brand medicines are having a moment — when household budgets get squeezed, shoppers trade down from branded products like Tylenol to cheaper generics, which is exactly what Perrigo makes. With a $1 billion market cap, the stock has fallen dramatically from its highs, making it either a deep value opportunity or a value trap depending on who you ask. The company is in the middle of a turnaround attempt, and whether it succeeds or fails will define the next few years.
How does it make money?
Perrigo pulls in about $4.3 billion in annual revenue by selling store-brand over-the-counter health products to retailers, who then put their own label on them. Their two main business arms are the Americas (think US pharmacy chains) and International (mainly Europe). Revenue slipped slightly from $4.4 billion the prior year, and the company posted a net loss of $1.4 billion last year — meaning they spent far more than they earned, largely due to legal settlements and writedowns on past acquisitions.
Why do investors care?
The core bet on Perrigo is that it is a fundamentally sound business going through a rough patch, not a broken one. If management can cut costs, resolve its legal headaches, and hold onto retail shelf space, the business could return to consistent profitability. The trade-down trend — shoppers choosing generics over expensive branded drugs — is a real tailwind that helps Perrigo's volumes. What has to go right: legal liabilities get resolved without further cash drain, margins recover, and the turnaround plan sticks.
Deep Dive
MemberA full investor briefing on Perrigo Company plc — history, leadership, risks, and outlook.